- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04562480
Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk
A Phase II Study of Hypofractionated Pre-Operative Radiation Therapy for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. To report the major acute wound complication rate associated with hypofractionated preoperative radiation therapy, 42.75 Gy in 15 fractions.
SECONDARY OBJECTIVES:
I. To report the 5-year local failure rate associated with hypofractionated preoperative radiation therapy, 42.75 Gy in 15 fractions.
II. To report the 5-year disease-free survival rate associated with hypofractionated preoperative radiation therapy, 42.75 Gy in 15 fractions.
III. To report the 5-year overall survival rate associated with hypofractionated preoperative radiation therapy, 42.75 Gy in 15 fractions.
IV. To report long-term toxicity rates associated with hypofractionated preoperative radiation therapy, 42.75 Gy in 15 fractions.
V. To describe patterns of relapse associated with hypofractionated preoperative radiation therapy, 42.75 Gy in 15 fractions.
VI. To describe patient reported outcomes/quality-of-life outcomes with hypofractionated preoperative radiation therapy, 42.75 Gy in 15 fractions.
OUTLINE:
Patients undergo hypofractionated radiation therapy once daily (QD) (except weekends and holidays) over 3 weeks for a total of 15 fractions. Within 3-6 weeks after completion of radiation therapy, patients undergo surgical resection.
After completion of study treatment, patients are followed up at 4-8 weeks, every 3-4 months for years 1-2, and every 6 months for years 3-5.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic in Arizona
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic in Florida
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Newly diagnosed, histological confirmation of soft tissue sarcoma of the extremities (including limb girdle) or superficial trunk that present as either -
- Deemed a candidate for complete macroscopic resection of the primary sarcoma OR
- Having had non-oncologic excisional procedure with positive or uncertain resection margins and still be eligible if the evaluating sarcoma surgeon recommends oncologic re-resection of the surgical bed to obtain negative margins after a course of preoperative radiation therapy
- No evidence of nodal or distant metastases as determined by clinical examination on any form of imaging
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 3
- Life expectancy greater than 6 months
- Patients capable of childbearing must use adequate contraception
- Ability to complete questionnaire(s) by themselves or with assistance
- Ability to provide written informed consent
- Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Exclusion Criteria:
- Previous radiation therapy to the site of the sarcoma or area surrounding it such that it would be encompassed by the radiation field needed to treat the current sarcoma. In other words, treatment on this trial would require re-irradiation of tissues
- Patients with nodal or distant metastases
- Rhabdomyosarcoma, soft tissue osteosarcoma, soft tissue Ewing sarcoma, and benign histologies
Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (hypofractionated radiation therapy, resection)
Patients undergo hypofractionated radiation therapy QD (except weekends and holidays) over 3 weeks for a total of 15 fractions.
Within 3-6 weeks after completion of radiation therapy, patients undergo surgical resection.
|
Ancillary studies
Other Names:
Ancillary studies
Undergo surgical resection
Other Names:
Undergo hypofractionated radiation therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients who experience major wound complications
Time Frame: Within 120 days of surgical resection of soft tissue sarcoma following preoperative radiation therapy
|
Will be estimated by the number of patients who experience the major wound complications within 120 days following surgery divided by the total number of evaluable patients.
Major wound complication is defined as secondary unplanned operation under general or regional anesthesia for wound repair (e.g.,debridement, operative drainage, or secondary wound closure including rotationplasty, free flaps or skin grafts); or wound management without secondary operation including invasive procedures (e.g., aspiration of seroma or readmission for wound care such as intravenous antibiotics or persistent deep packing for 120 days or longer).
95% confidence intervals using normal approximation to binomial wound complication proportion will be calculated.
|
Within 120 days of surgical resection of soft tissue sarcoma following preoperative radiation therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Local failure rate
Time Frame: At 5 years
|
Will be defined any radiographic or pathologic evidence of recurrent disease inside the clinical target volume (CTV) and/ or to within 3 cm from the edge of the CTV.
Local failure rate at 5 years (LFR5) will be evaluated by the number of patients free of local failure/recurrence at 5 year divided by the total number of evaluable patients.
Exact binomial 95% confidence interval for the point estimate will be provided.
In the case of censoring prior to 5 years, LFR5 will be estimated using the Kaplan-Meier method.
|
At 5 years
|
Disease-free survival
Time Frame: From registration date to the earliest date of documentation of either, local recurrence, regional recurrence, distant recurrence, or death due to any cause, assessed up to 5 years
|
The distribution of disease-free survival will be estimated using method of Kaplan-Meier.
|
From registration date to the earliest date of documentation of either, local recurrence, regional recurrence, distant recurrence, or death due to any cause, assessed up to 5 years
|
Overall survival
Time Frame: From registration date to death due to any cause, assessed up to 5 years
|
The distribution of overall survival will be estimated using method of Kaplan-Meier.
|
From registration date to death due to any cause, assessed up to 5 years
|
Incidence of late adverse events
Time Frame: Between 3 months and 24 months after completion of hypofractionated preoperative radiation therapy
|
The descriptions and grading scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for adverse event reporting.
The rate of >= grade 2 late adverse events will be estimated by the number of patients with a >= grade 2 late adverse event divided by the total number of evaluable patients.
Exact binomial 95% confidence intervals for the true rate of >= grade 2 late adverse events will be calculated.
|
Between 3 months and 24 months after completion of hypofractionated preoperative radiation therapy
|
Pattern of relapse
Time Frame: Up to 5 years
|
Pattern of relapse will be evaluated by number of patients with patterns of tumor recurrence such as local recurrence, marginal recurrence, regional recurrence, distant metastasis, and second primary tumor divided by the total number of evaluable patients.
Exact binomial 95% confidence interval for the point estimate will be provided.
|
Up to 5 years
|
Incidence of adverse events
Time Frame: Up to 5 years
|
The descriptions and grading scales found in the revised NCI CTCAE version 5.0 will be utilized for adverse event reporting.
The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns.
Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.
|
Up to 5 years
|
Change in quality of life - PROMIS-10
Time Frame: Baseline up to 24 months post-surgery
|
Results from the ten-item Patient Reported Outcomes Measurement Information System (PROMIS-10) questionnaire will be used to evaluate physical and mental health separately.
The Wilcoxon signed-rank test will be utilized to assess changes in raw PROMIS scores.
Mean change, along with standard deviation will be reported.
The PROMIS-10 consists of ten items that measure physical health, physical functioning, general mental health, emotional distress, satisfaction with social activities and relationships, ability to carry out usual social activities and roles, pain, fatigue and overall quality of life.
|
Baseline up to 24 months post-surgery
|
Change in quality of life - TESS
Time Frame: Baseline up to 24 months post-surgery
|
Results from the Toronto Extremity Salvage Score (TESS) questionnaire will be used to evaluate functional outcomes.
Mean change from baseline to 24 months post-surgery, along with standard deviation will be reported by version.
The TESS was designed as a measure of the difficulty patients have performing routine daily activities.
It consists of 31 items with responses from 1 (impossible to do) to 5 (not at all difficult).
|
Baseline up to 24 months post-surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Safia K. Ahmed, M.D., Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MC1973 (Other Identifier: Mayo Clinic in Rochester)
- NCI-2020-06811 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 19-011871 (Other Identifier: Mayo Clinic Institutional Review Board)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
-
M.D. Anderson Cancer CenterRecruitingStage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Resectable... and other conditionsUnited States
-
University of WashingtonExelixisActive, not recruitingStage I Soft Tissue Sarcoma of the Trunk and Extremities | Stage II Soft Tissue Sarcoma of the Trunk and Extremities | Sarcoma of the Extremity | Stage IA Soft Tissue Sarcoma of the Trunk and Extremities | Stage IB Soft Tissue Sarcoma of the Trunk and ExtremitiesUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight TherapeuticsActive, not recruitingLeiomyosarcoma | Malignant Peripheral Nerve Sheath Tumor | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Undifferentiated High Grade Pleomorphic Sarcoma of Bone | Myxofibrosarcoma | Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingSoft Tissue Sarcoma | Stage I Soft Tissue Sarcoma of the Trunk and Extremities | Stage II Soft Tissue Sarcoma of the Trunk and Extremities | Stage III Soft Tissue Sarcoma of the Trunk and ExtremitiesUnited States
-
Roswell Park Cancer InstituteIncuronTerminatedClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Advanced Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Locally Advanced Dedifferentiated Liposarcoma | Unresectable Dedifferentiated...United States
-
National Cancer Institute (NCI)Active, not recruitingSoft Tissue Sarcoma | Leiomyosarcoma | Liposarcoma | Undifferentiated Pleomorphic Sarcoma | Soft Tissue Sarcoma of the Trunk and Extremities | Stage I Soft Tissue Sarcoma AJCC v7 | Stage II Soft Tissue Sarcoma AJCC v7 | Sarcoma G2 | Sarcoma G3United States, Canada
-
Italian Sarcoma GroupFrench Sarcoma Group; Grupo Espanol de Investigacion en SarcomasActive, not recruitingLocalized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in AdultsSpain, Italy
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IIIC Uterine Corpus Leiomyosarcoma... and other conditionsUnited States
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditionsUnited States